ERBB2 status and outcome of endocrine treatment

The Lancet Oncology

Volumn 9, Issue 1, 2008, Pages 4-5

  Miller, WR ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; EXEMESTANE; LETROZOLE; PROGESTERONE RECEPTOR; TAMOXIFEN; TRASTUZUMAB;

ADJUVANT THERAPY; BREAST CANCER; CANCER HORMONE THERAPY; CELL PROLIFERATION; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; GENE OVEREXPRESSION; HUMAN; LETTER; MONOTHERAPY; POSTMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; FEMALE; HUMANS; NITRILES; POSTMENOPAUSE; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TAMOXIFEN; TRIAZOLES;

EID: 37449009762     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(07)70389-3     Document Type: Letter

References (12)

1. Clemons M., Danson S., and Howell A. Tamoxifen ('Nolvadex'): a review. Cancer Treat Rev 28 (2002) 165-180
2. Buzdar A. Aromatase inhibitors: changing the face of endocrine therapy for breast cancer. Breast Dis 24 (2005-2006) 107-117
3. Dowsett M., Cuzick J., Wale C., et al. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol 23 (2005) 7512-7517
4. Viale G., Regan M., Maiorano E., et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal women with early breast cancer: BIG 1-98. J Clin Oncol 25 (2007) 3846-3852
5. Slamon D., Clark G., Wong S., et al. Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 235 (1987) 177-182
6. Dowsett M., Houghton J., Iden C., et al. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol 17 (2006) 818-826
7. Ellis M., Coop A., Singh B., et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for erbB-1- and/or erbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19 (2001) 3808-3816
8. Miller W., Bartlett J., Canney P., et al. Hormonal therapy for postmenopausal breast cancer: the science of sequencing. Breast Cancer Res Treat 103 (2007) 149-160
9. Rasmussen B., Regan M., Lykkesfeldt A., et al. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol 8 (2007) 23-28
10. Dowsett M, Allred C, Knox J, et al. Relationship between quantitative estrogen and progesterone receptor expression and HER2 status with recurrence in the ATAC trial. J Clin Oncol (in press).
11. Dixon J., Jackson J., Hills M., et al. Anastrozole demonstrates clinical and biological effectiveness in oestrogen receptor-positive breast cancers, irrespective of the erbB2 status. Eur J Cancer 40 (2004) 2742-2747
12. Ellis M., Tao Y., Young O., et al. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. J Clin Oncol 24 (2006) 3019-3024